Indikation (Clinical Trials):
Breast Neoplasms, Recurrence
Geschlecht:
Frauen
Altersgruppe:
Erwachsene (18+)
Phase:
-
Sponsor:
University Hospital Tuebingen
Collaborator:
-
Kontakt
Andreas Hartkopf, MD Kontakt: Phone: 4970712982211 E-Mail: andreas.hartkopf@med.uni-tuebingen.de» Kontaktdaten anzeigen
Studienlocations (1 von 1)
Department for Women's Health 72086 Tübingen (Baden-Württemberg) GermanyRekrutierend» Google-Maps Ansprechpartner: Brucker Sara, MD» Ansprechpartner anzeigen
1. Evaluation of the influence of the 21-gene Recurrence-Score (RS) on adjuvant therapy recommendation (Time Frame - 1 year): The Recurrence Score is a continuous score that provides an individual estimate of the 10 year risk of distant recurrence and predicts the likelihood of benefit from chemotherapy. The quantitative nature of PCR allows for a continuous score as opposed to a binary result (low vs. high only). Oncotype DX test results assign a Recurrence Score - a number between 0 and 100 - to the early-stage breast cancer or DCIS.
Recurrence Score lower than 18: The cancer has a low risk of recurrence. The benefit of chemotherapy is likely to be small and will not outweigh the risks of side effects.
Recurrence Score of 18 up to and including 30: The cancer has an intermediate risk of recurrence. It's unclear whether the benefits of chemotherapy outweigh the risks of side effects.
Recurrence Score greater than or equal to 31: The cancer has a high risk of recurrence, and the benefits of chemotherapy are likely to be greater than the risks of side effects.
Secondary outcome:
1. Evaluation of the association of the RS with tumor cell dissemination into bone marrow (Time Frame - 1 year): Bone marrow sampling is performed during primary surgery as part of the clinical routine. The presence of disseminated tumor cells (DTC status) is evaluated by immunostaining.
2. Correlation of the RS with age (Time Frame - 1 year): age in years
3. Correlation of the RS with tumor nodal status (Time Frame - 1 year)
4. Correlation of the RS with tumor grading (Time Frame - 1 year)
5. Correlation of the RS with proliferation marker Ki-67 (Time Frame - 1 year)
Quelle: ClinicalTrials.gov
Sie können folgenden Inhalt einem Kollegen empfehlen:
"Impact of Recurrence Score on Adjuvant Treatment Decisions in Breast Cancer Patients"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!